Redeye comments on Azelio's Q2 report, which held no surprises.
Redeye states that Catella's Q2 report came in strong and in line with our expectations.
Enligt estimat Guard Therapeutics rapport för det andra kvartalet var i linje med vår förväntan.
Ökar antalet licenser med 6% q/q Försäljningen för kvartalet kom in på 6,0 mkr (6,0), vilket var und...
Kostnaderna under förväntan Omsättningen uppgick som väntat till 0 mkr under Q2'21.
Redeye continues to view Scibase in a positive light after the Q2 report yesterday.
Redeye believes the Q2 report supports our view that flagship project Emcitate is on track.
Redeye comments on Dignitana's Q2 report. The sales development continues to be positive in uncertai...
Endomines’ Q2 was focused on production start-up and with delays at Friday serious production figure...
Marimekko’s Q2 figures came in above estimates. The company is still only laying out the foundation ...
Tobii’s Q2 numbers were a miss on top line and primarily EBIT.
Q2 operating losses increased y/y, as we anticipated, due to the applied and initiated studies annou...
Important events during and after the quarter Important events during the quarter included the start...
Q2 Adj. EBIT came in at SEK 113m, vs. ABG at SEK 69m Catella reported a Q2’21 EBIT of SEK -31m (39m), compared to ABGSC which expected SEK -...
An intriguing opportunity to tap into the private fintech market VEF is an investment company founde...
Q2 results: sales in line but margins lower than expected Sales were in line with our estimates at S...
Considerable cuts in travel expense expected long-term Today we had the pleasure of hosting CEO Jon Sigurdsson, for our ABGSC conference cal...
Q1 revenues of SEK 19m for y-o-y growth of -20.9% Precise Biometrics’ Q2’21 report was below our est...
Redeye är uppmuntrade av framsteg i kombinationsstudien med CAN04 och Keytruda.
Intellego Technologies publicerade idag den 19 augusti 2021 sin delårsrapport för andra kvartalet 2021.
Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter.
Redeye maintains our view of Annexin Pharmaceuticals and Base case of SEK 4 following the company’s ...
Carasent reported a stable quarter with good customer intake and clear signs of scalability.
Q2 EBIT of SEK 43m, -30% vs. ABGSCe, -20% vs. cons.
Nettoomsättningen sjönk till 0,4 mkr (1,5 mkr) vilket var under vår förväntan om 1,5 mkr.
Redeye leaves a comment on Acarix following the release of its Q2 report.
Redeye provides its take on the Q2 report where we note an encouraging engagement among clinics, tho...
